MDNAF — Medicenna Therapeutics Corp.

—
OTC · Health Care · Pharmaceuticals · CIK 1807983 · Ontario, Canada
Last close
$0.16
Market Cap
$14.77M
52W High
$1.30
52W Low
$0.16
ADV30
49,770
Next earnings
2027-02-11

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -5,451,000 -5,082,000 8,249,000 5,691,000 6,576,000
Mar 2026 0 — -5,822,000 -4,234,000 8,454,000 6,251,000 5,972,000
Dec 2025 0 — -5,616,000 -4,364,000 13,065,000 10,614,000 6,853,000
Sep 2025 0 — -5,470,000 -4,883,000 18,041,000 15,748,000 7,799,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,807,000
Investing CF
$2,000
Financing CF
$3,819,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-141,743,000
Inventory
—
Receivables
$1,523,000
ST Investments
—
EBIT TTM
$-22,359,000
Pretax Income TTM
$-18,563,000
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 0 -22,417,000 -18,409,000 8,454,000 5,972,000 2,482,000 -17,923,000
Mar 2025 0 -20,406,000 -11,805,000 28,382,000 9,287,000 19,095,000 -16,492,000
Mar 2024 0 -18,674,000 -25,466,000 19,134,000 13,943,000 5,191,000 -16,260,000
Mar 2023 0 -16,303,000 -10,048,000 36,446,000 6,960,000 29,486,000 -12,657,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.17

Peers — same industry

TickerNameMarket CapLastDaily %
BOLT Bolt Biotherapeutics, Inc. $14.73M $5.65 —
KTTA Pasithea Therapeutics Corp. $14.51M $0.43 —
MCRB Seres Therapeutics, Inc. $14.37M $1.41 —
CTXR Citius Pharmaceuticals, Inc. $14.24M $0.52 —
NCEL NewcelX Ltd. $15.48M $2.68 —

News headlines (Yahoo Finance, 1h cache)

Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update
2026-11-17 12:45 · Yahoo
Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Con
2026-11-16 12:00 · Yahoo
Medicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies
2026-11-09 12:00 · Yahoo
Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
2026-11-04 12:00 · Yahoo
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
2026-10-26 12:52 · Yahoo
Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference
2026-10-22 11:00 · Yahoo
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
2026-10-05 13:00 · Yahoo
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
2026-10-01 23:00 · Yahoo
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
2026-09-24 11:00 · Yahoo
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.